Cargando…

Impact of Lactobacillus reuteri Supplementation on Anti-Helicobacter pylori Levofloxacin-Based Second-Line Therapy

Introduction. Helicobacter pylori eradication therapy has the potential burden of antibiotic-associated gastrointestinal (GI) side effects. The occurrence of side effects is among the major drawbacks of such regimens. GI manifestations may be related to alterations in the intestinal microflora. Prob...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ojetti, Veronica, Bruno, Giovanni, Ainora, Maria Elena, Gigante, Giovanni, Rizzo, Gianluca, Roccarina, Davide, Gasbarrini, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368352/ https://www.ncbi.nlm.nih.gov/pubmed/22690211 http://dx.doi.org/10.1155/2012/740381

Ejemplares similares

Inclusion of Lactobacillus Reuteri in the Treatment of Helicobacter pylori in Sardinian Patients: A Case Report Series
por: Dore, Maria P., et al.
Publicado: (2016)

The effect of Lactobacillus reuteri supplementation in Helicobacter pylori infection: a placebo-controlled, single-blind study
por: Buckley, Martin, et al.
Publicado: (2018)

Lactobacillus reuteri versus triple therapy for the eradication of Helicobacter pylori in functional dyspepsia
por: Muresan, Iulia Antonia Pop, et al.
Publicado: (2019)

Lactobacillus Reuteri DSM 17938 (Limosilactobacillus reuteri) in Diarrhea and Constipation: Two Sides of the Same Coin?
por: Saviano, Angela, et al.
Publicado: (2021)

The Clinical and Bacteriological Factors for Optimal Levofloxacin-Containing Triple Therapy in Second-Line Helicobacter pylori Eradication
por: Tai, Wei-Chen, et al.
Publicado: (2014)

Resistance of Helicobacter pylori to furazolidone and levofloxacin: A viewpoint
por: Zamani, Mohammad, et al.
Publicado: (2017)

A Randomized Control Trial Comparing 2 Levofloxacin-Containing Second-Line Therapies for Helicobacter pylori Eradication
por: Chuah, Seng-Kee, et al.
Publicado: (2016)

Non-Viable Lactobacillus reuteri DSMZ 17648 (Pylopass™) as a New Approach to Helicobacter pylori Control in Humans
por: Mehling, Heidrun, et al.
Publicado: (2013)

Metagenomic Changes of Gut Microbiota following Treatment of Helicobacter pylori Infection with a Simplified Low-Dose Quadruple Therapy with Bismuth or Lactobacillus reuteri
por: Dore, Maria Pina, et al.
Publicado: (2022)

First- and second-line Helicobacter pylori eradication with modified sequential therapy and modified levofloxacin-amoxicillin-based triple therapy
por: Zullo, Angelo, et al.
Publicado: (2014)

Levofloxacin-containing triple therapy versus bismuth-based quadruple therapy as regimens for second line anti- Helicobacter pylori
por: Seyyedmajidi, Mohamadreza, et al.
Publicado: (2019)

Limosilactobacillus reuteri Strains as Adjuvants in the Management of Helicobacter pylori Infection
por: Dargenio, Costantino, et al.
Publicado: (2021)

Significant Reduction in Helicobacter pylori Load in Humans with Non-viable Lactobacillus reuteri DSM17648: A Pilot Study
por: Holz, Caterina, et al.
Publicado: (2014)

Molecular and Proteomic Analysis of Levofloxacin and Metronidazole Resistant Helicobacter pylori
por: Hanafi, Aimi, et al.
Publicado: (2016)

Ten-Day versus 14-Day Levofloxacin-Containing Triple Therapy for Second-Line Anti-Helicobacter pylori Eradication in Taiwan
por: Tai, Wei-Chen, et al.
Publicado: (2013)

Levofloxacin, Metronidazole, and Lansoprazole Triple Therapy Compared to Quadruple Therapy as a Second-Line Treatment of Helicobacter pylori Infection in Korea
por: Moon, Ji Yoon, et al.
Publicado: (2013)

Clinical Implications of Helicobacter pylori Antibiotic Resistance in Italy: A Review of the Literature
por: Nista, Enrico Celestino, et al.
Publicado: (2022)

Rifaximin Plus Levofloxacin-Based Rescue Regimen for the Eradication of Helicobacter pylori
por: Yun, Sang-Pil, et al.
Publicado: (2012)

Comparison of levofloxacin versus clarithromycin efficacy in the eradication of Helicobacter pylori infection
por: Haji-Aghamohammadi, Ali Akbar, et al.
Publicado: (2016)

Emerging Helicobacter pylori levofloxacin resistance and novel genetic mutation in Nepal
por: Miftahussurur, Muhammad, et al.
Publicado: (2016)

Role of Probiotics in Helicobacter pylori Eradication: Lessons from a Study of Lactobacillus reuteri Strains DSM 17938 and ATCC PTA 6475 (Gastrus®) and a Proton-Pump Inhibitor
por: Dore, Maria Pina, et al.
Publicado: (2019)

Beneficial effects of Helicobacter pylori eradication on migraine: a 12-month follow-up study
por: Gabrielli, Maurizio, et al.
Publicado: (2001)

The Influence of Helicobacter pylori on Human Gastric and Gut Microbiota
por: Fiorani, Marcello, et al.
Publicado: (2023)

Efficacy of Levofloxacin-Based Third-Line Therapy for the Eradication of Helicobacter pylori in Peptic Ulcer Disease
por: Lim, Joo Hyun, et al.
Publicado: (2017)

Celiac Disease and Myointimal Proliferation: A Possible Correlation?
por: Merra, Giuseppe, et al.
Publicado: (2008)

Variability in Prevalence of Helicobacter pylori Strains Resistant to Clarithromycin and Levofloxacin in Southern Poland
por: Karczewska, Elżbieta, et al.
Publicado: (2012)

Surveillance of Levofloxacin Resistance in Helicobacter pylori Isolates in Bogotá-Colombia (2009-2014)
por: Trespalacios-Rangél, Alba A., et al.
Publicado: (2016)

Cefuroxime, levofloxacin, esomeprazole, and bismuth as first-line therapy for eradicating Helicobacter pylori in patients allergic to penicillin
por: Song, Zhiqiang, et al.
Publicado: (2019)

Efficacy of Levofloxacin Based Triple and High-Dose PPI-Amoxicillin Dual Eradication Therapy for Helicobacter pylori after Failures of First- and Second-Line Therapies
por: Okimoto, Kenichiro, et al.
Publicado: (2014)

Pistacia vera L. oleoresin and levofloxacin is a synergistic combination against resistant Helicobacter pylori strains
por: Di Lodovico, Silvia, et al.
Publicado: (2019)

The Comparison of Levofloxacin- and Clarithromycin-Based Bismuth Quadruple Therapy Regimens in Helicobacter pylori Eradication
por: Arj, Abbas, et al.
Publicado: (2020)

Phenotype and Molecular Detection of Clarithromycin and Levofloxacin Resistance in Helicobacter pylori Clinical Isolates in Beijing
por: Lok, Chong-Hou, et al.
Publicado: (2020)

Lactobacillus rhamnosus GG supplementation on eradication rate and dyspepsia in Helicobacter pylori infection treated with three-in-one bismuth quadruple therapy
por: Marinelli, Paride, et al.
Publicado: (2022)

Efficacy and Safety of the Triple Therapy Containing Ilaprazole, Levofloxacin, and Amoxicillin as First-Line Treatment in Helicobacter pylori Infections
por: Ahn, Hyo Jun, et al.
Publicado: (2017)

Polyphenols and Lactobacillus reuteri in oral health
por: NAUREEN, ZAKIRA, et al.
Publicado: (2022)

Microbiota and Probiotics: The Role of Limosilactobacillus Reuteri in Diverticulitis
por: Piccioni, Andrea, et al.
Publicado: (2021)

Design and evaluation of gastroretentive levofloxacin floating mini-tablets-in-capsule system for eradication of Helicobacter pylori
por: El-Zahaby, Sally A., et al.
Publicado: (2014)

Alternative eradication regimens for Helicobacter pylori infection in Indonesian regions with high metronidazole and levofloxacin resistance
por: Miftahussurur, Muhammad, et al.
Publicado: (2019)

Five alternative Helicobacter pylori antibiotics to counter high levofloxacin and metronidazole resistance in the Dominican Republic
por: Miftahussurur, Muhammad, et al.
Publicado: (2019)

Evaluation of multiplex ARMS-PCR for detection of Helicobacter pylori mutations conferring resistance to clarithromycin and levofloxacin
por: Li, Yangxia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pspkj382t18ulp1ls24djvvses